Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Kidney cancer

AXL expression predicts prognosis

Nature Reviews Urology volume 14, page 700 (2017)Cite this article

Subjects

Access through your institution
Buy or subscribe

Patients with AXL expression had shorter overall survival

New data published in Urologic Oncology show that increased expression of the receptor tyrosine kinase AXL is associated with worse clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) who have previously received sunitinib. Thus, AXL expression could be a prognostic biomarker for patients with this disease.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Zucca, L. E. et al. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol. Oncol. http://dx.doi.org/10.1016/j.urolonc.2017.09.003 (2017)

Download references

Authors
  1. Louise Stone
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stone, L. AXL expression predicts prognosis. Nat Rev Urol 14, 700 (2017). https://doi.org/10.1038/nrurol.2017.186

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2017.186

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer